report oper result yesterday market
close guidanc outlook provid overal
product sale came ahead expect one-tim
inventori charg weigh earn product sale guidanc
rang consensu albeit sever risk
uncertainti highlight given potenti headwind base
hiv/hcv busi view pipelin success aggress busi
develop key would highlight view favor
risk reward nash phase data
maintain outperform rate reduc
price target follow review result focu
result product perform report non-gaap
ep vs consensu total revenu vs
consensu one-tim neg ep impact
reserv excess harvoni inventori product sale
perform includ hiv sale vs
consensu sequenti growth year-over-year yoy
growth hcv product sale show continu declin
vs mm consensu sequenti
yoy declin final yescarta sale vs
consensu factor expect impact sale perform
includ ex-u hiv gener gener letairi ranexa
potenti lower hcv start price pressur
guidanc product sale vs
consensu expect double-digit global hiv sale growth
off-set hcv declin return
growth trough earn expens guidanc
includ vs consensu sg
vs increment pre-launch cost
selonsertib filgotinib cash roughli
describ provid strateg flexibl capit alloc
prioriti a/partnership dividend share repurchas
continu page
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
addit focu pipelin progress highlight phase data read-out expect
stellar stellar studi inhibitor selonsertib non-alcohol steatohepat
nash fibrosi well finch finch studi select inhibitor
filgotinib rheumatoid arthriti ra discov studi descovi prep hiv prevent
nash data immin stellar stellar suggest file
singl studi success would discuss fda regulatori file filgotinib gate safeti
data manta studi ulcer coliti uc enrol rate describ increas final
cell therapi focu remain move yescarta earlier line dlbcl b-cell malign
next-gener allogen car-t enter clinic focu novel approach cell
therapi solid tumor
price target
arriv price target appli multipl ep estim risk includ
continu slow hcv patient volum emerg credibl competit threat merck
particular failur key pipelin program hbv nash failur secur meaning revenu
opportun
expect stabil hcv trend visibl trough earn offset growth hiv product
emerg pipelin focus cell therapi cancer immunolog nash support out-performance
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
